Korro Bio, Inc.
KRRO
NASDAQ·Healthcare·Biotechnology·Mkt cap $115.7M
$11.62
▼ -2.92%
P/E
-1.16
Mkt Cap
$115.7M
52-Wk Range
$5.20–$55.89
52-Week Range
$5.20 - $55.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 58.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary RNA editing technology platform with selective modification capabilities
- Experienced management team with deep expertise in genetic medicine and biotechnology
- Diversified pipeline targeting both rare and prevalent diseases with large market opportunities
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Stable outlook
Clinical trial advancement and regulatory approvals for pipeline candidates
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+3.9% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KRRO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 6, 2026
Reported EPS of -$1.07 vs -$1.34 consensus (+20.1% surprise). Revenue of $1.5M vs $214.3K expected (+600.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.1%
Revenue trend · last 8Q
—
—
—
—
—
-43%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$2.3M
$2.5M
$1.5M
$1.1M
$1.3M
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · $15.00 · May 19, 2026
vs Industry
How KRRO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related